Our Mission

Muscle and bone disorders represent a tremendous and further increasing health burden affecting the quality of life of millions of people. The mission of Sirana Pharma is to develop therapies for unmet medical needs in musculoskeletal diseases. To accomplish our mission, we pioneer novel biological approaches and mechanisms to generate innovative first-in-class drugs that improve the integrity and function of diseased skeletal muscle and bone tissues.


Management Team​

Extended Team

Scientific Advisory Board



Announcements of corporate news and company updates.

Sirana Pharma appoints new CEO

Sirana Pharma GmbH announces the appointment of Dr. Oliver von Stein as its new CEO. Dr. von Stein is a serial entrepreneur and brings a wealth of experience with over 20 years of C-level leadership experience in the Biopharma industry. He has led all aspects of corporate development including product approval, advancing drug candidates to phase III and growing companies to IPO listing. He has a proven business development track record, including major out-licensing deals with biotech and Pharma.

“Sirana Pharma has a unique and differentiated approach to the treatment of musculoskeletal disorders using its proprietary knowledge of micro-RNA targets. I am thrilled to be joining Sirana Pharma at this exciting time and to be part of such a talented and experienced leadership team. I look forward to the challenge of building the company and to strengthen Sirana Pharma’s position as a leader in miRNA targeting drugs.”

Sirana Pharma enters into a collaborative research agreement with Pfizer to investigate a novel treatment for a rare bone disease

Sirana Pharma GmbH announces today a collaborative research agreement with Pfizer Inc. to investigate the potential identification and validation of a novel treatment concept for a rare bone disease. The collaboration will utilize Sirana’s proprietary microRNA (miRNA)-targeting approach, which targets substantial regenerative recovery of diseased muscle and bone tissue.


Share this page